MedPath

An Observational Registry of Abatacept in Patients With Juvenile Idiopathic Arthritis

Active, not recruiting
Conditions
Juvenile Idiopathic Arthritis
Registration Number
NCT01357668
Lead Sponsor
Bristol-Myers Squibb
Brief Summary

The purpose of this study is to examine the long-term safety of Abatacept for the treatment of juvenile idiopathic arthritis (JIA) with particular in interest in the occurrence of serious infections, autoimmune disorders, and malignancies.

Detailed Description

Not available

Recruitment & Eligibility

Status
ACTIVE_NOT_RECRUITING
Sex
All
Target Recruitment
800
Inclusion Criteria
  • Diagnosis of JIA (any subtype)
  • Age < 18 years at the time of enrollment unless currently or previously enrolled in an abatacept clinical trial and received abatacept
  • Receiving Abatacept at the time of enrollment as per treating physician's decision or received abatacept in a clinical trial
  • Parent or legally acceptable representative willing to participate in the study and sign the informed consent
Exclusion Criteria
  • Pregnant or nursing female at the time of enrollment
  • Prior malignancies if the patient has not been malignancy free for at least 5 years.
  • Any serious acute or chronic medical condition other than JIA, including chronic infection, which would compromise the patient's ability to participate in the study
  • Known poor compliance with clinic visits (based on physician judgment)

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Incidence rate of serious infections10 years
Incidence rate of malignancies10 years
Incidence rate of autoimmune disorders10 years
Secondary Outcome Measures
NameTimeMethod
Number of serious adverse events10 years
Number of targeted infections (Epstein-Barr virus, cytomegalovirus, papilloma virus, herpes zoster, tuberculosis and opportunistic infections)10 years

Trial Locations

Locations (59)

Local Institution - 0060

๐Ÿ‡บ๐Ÿ‡ธ

Little Rock, Arkansas, United States

Local Institution - 0001

๐Ÿ‡บ๐Ÿ‡ธ

Princeton, New Jersey, United States

Local Institution - 0059

๐Ÿ‡บ๐Ÿ‡ธ

Cincinnati, Ohio, United States

Local Institution - 0025

๐Ÿ‡ฆ๐Ÿ‡น

Bregenz, Austria

Local Institution - 0002

๐Ÿ‡ฆ๐Ÿ‡น

Innsbruck, Austria

Local Institution - 0032

๐Ÿ‡ฆ๐Ÿ‡น

Vienna, Austria

Local Institution - 0010

๐Ÿ‡ง๐Ÿ‡ท

Botucatu, Sao Paulo, Brazil

Local Institution - 0028

๐Ÿ‡ง๐Ÿ‡ท

Sรฃo Paulo, SAO Paulo, Brazil

Local Institution - 0026

๐Ÿ‡ง๐Ÿ‡ท

Campinas, Sรฃo Paulo, Brazil

Local Institution - 0027

๐Ÿ‡ง๐Ÿ‡ท

Rio De Janeiro, Brazil

Local Institution - 0029

๐Ÿ‡จ๐Ÿ‡ฆ

Calgary, Alberta, Canada

Local Institution - 0011

๐Ÿ‡จ๐Ÿ‡ฆ

Montreal, Quebec, Canada

Local Institution - 0035

๐Ÿ‡ฉ๐Ÿ‡ฐ

Aarhus, Midtjylland, Denmark

Local Institution - 0012

๐Ÿ‡ฉ๐Ÿ‡ฐ

Copenhagen, Denmark

Local Institution - 0040

๐Ÿ‡ซ๐Ÿ‡ท

Clermont-ferrand, Puy-de-Dรดme, France

Local Institution - 0005

๐Ÿ‡ซ๐Ÿ‡ท

Paris Cedex 15, France

Local Institution - 0041

๐Ÿ‡ซ๐Ÿ‡ท

Toulouse cedex 9, France

Local Institution - 0003

๐Ÿ‡ฉ๐Ÿ‡ช

Bad Bramstedt, Germany

Local Institution - 0030

๐Ÿ‡ฉ๐Ÿ‡ช

Berlin, Germany

Local Institution - 0034

๐Ÿ‡ฉ๐Ÿ‡ช

Freiburg, Germany

Local Institution - 0031

๐Ÿ‡ฉ๐Ÿ‡ช

Hamburg, Germany

Local Institution - 0033

๐Ÿ‡ฉ๐Ÿ‡ช

Heidelberg, Germany

Local Institution - 0016

๐Ÿ‡ฌ๐Ÿ‡ท

Thessaloniki, Greece

Local Institution - 0017

๐Ÿ‡ญ๐Ÿ‡บ

Budapest, Hungary

Local Institution - 0014

๐Ÿ‡ฎ๐Ÿ‡ฑ

Jerusalem, Israel

Local Institution - 0042

๐Ÿ‡ฎ๐Ÿ‡น

Firenze, Italy

Local Institution - 0015

๐Ÿ‡ฎ๐Ÿ‡น

Genova, Italy

Local Institution - 0043

๐Ÿ‡ฎ๐Ÿ‡น

Naples, Italy

Local Institution - 0045

๐Ÿ‡ฎ๐Ÿ‡น

Napoli, Italy

Local Institution - 0044

๐Ÿ‡ฎ๐Ÿ‡น

Padova, Italy

Local Institution - 0046

๐Ÿ‡ฎ๐Ÿ‡น

Trento, Italy

Local Institution - 0018

๐Ÿ‡ฑ๐Ÿ‡ป

Riga, Latvia

Local Institution - 0006

๐Ÿ‡ฒ๐Ÿ‡ฝ

Guadalajara, Jalisco, Mexico

Local Institution - 0047

๐Ÿ‡ณ๐Ÿ‡ฑ

Rotterdam, Netherlands

Local Institution - 0019

๐Ÿ‡ณ๐Ÿ‡ฑ

Utrecht, Netherlands

Local Institution - 0048

๐Ÿ‡ณ๐Ÿ‡ด

Tromso, Norway

Local Institution - 0049

๐Ÿ‡ณ๐Ÿ‡ด

Trondheim, Norway

Local Institution - 0007

๐Ÿ‡ต๐Ÿ‡ช

Lima, Peru

Local Institution - 0050

๐Ÿ‡ต๐Ÿ‡ช

Lima, Peru

Local Institution - 0020

๐Ÿ‡ต๐Ÿ‡น

Lisboa, Portugal

Local Institution - 0023

๐Ÿ‡ต๐Ÿ‡ท

Bayamon, Puerto Rico

Local Institution - 0056

๐Ÿ‡ต๐Ÿ‡ท

Bayamon, Puerto Rico

Local Institution - 0021

๐Ÿ‡ท๐Ÿ‡ด

Cluj-Napoca, Romania

Local Institution - 0051

๐Ÿ‡ท๐Ÿ‡บ

Moscow, Russian Federation

Local Institution

๐Ÿ‡ท๐Ÿ‡บ

Moscow, Russian Federation

Local Institution - 0053

๐Ÿ‡ท๐Ÿ‡บ

Saint-Petersburg, Russian Federation

Local Institution - 0052

๐Ÿ‡ท๐Ÿ‡บ

Saratov, Russian Federation

Local Institution - 0055

๐Ÿ‡ธ๐Ÿ‡ฆ

Jeddah, Saudi Arabia

Local Institution - 0024

๐Ÿ‡ธ๐Ÿ‡ฆ

Riyadh 11426, Saudi Arabia

Local Institution - 0022

๐Ÿ‡ธ๐Ÿ‡ฐ

Piestany, Slovakia

Local Institution - 0009

๐Ÿ‡ฟ๐Ÿ‡ฆ

Pretoria, Gauteng, South Africa

Local Institution - 0057

๐Ÿ‡ฟ๐Ÿ‡ฆ

Panorama, Cape Town, Western CAPE, South Africa

Local Institution - 0058

๐Ÿ‡ฟ๐Ÿ‡ฆ

Pretoria, South Africa

Local Institution - 0036

๐Ÿ‡ช๐Ÿ‡ธ

Sant Joan Despรญ, Barcelona, Spain

Local Institution - 0004

๐Ÿ‡ช๐Ÿ‡ธ

Barcelona, Spain

Local Institution - 0038

๐Ÿ‡ช๐Ÿ‡ธ

Madrid, Spain

Local Institution - 0037

๐Ÿ‡ช๐Ÿ‡ธ

Murcia, Spain

Local Institution - 0039

๐Ÿ‡ช๐Ÿ‡ธ

Valencia, Spain

Local Institution - 0013

๐Ÿ‡ฌ๐Ÿ‡ง

Bristol, United Kingdom

ยฉ Copyright 2025. All Rights Reserved by MedPath